233 related articles for article (PubMed ID: 34857016)
1. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.
Alors-Perez E; Blázquez-Encinas R; Alcalá S; Viyuela-García C; Pedraza-Arevalo S; Herrero-Aguayo V; Jiménez-Vacas JM; Mafficini A; Sánchez-Frías ME; Cano MT; Abollo-Jiménez F; Marín-Sanz JA; Cabezas-Sainz P; Lawlor RT; Luchini C; Sánchez L; Sánchez-Hidalgo JM; Ventura S; Martin-Hijano L; Gahete MD; Scarpa A; Arjona-Sánchez Á; Ibáñez-Costa A; Sainz B; Luque RM; Castaño JP
J Exp Clin Cancer Res; 2021 Dec; 40(1):382. PubMed ID: 34857016
[TBL] [Abstract][Full Text] [Related]
2. Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma.
López-Cánovas JL; Del Rio-Moreno M; García-Fernandez H; Jiménez-Vacas JM; Moreno-Montilla MT; Sánchez-Frias ME; Amado V; L-López F; Fondevila MF; Ciria R; Gómez-Luque I; Briceño J; Nogueiras R; de la Mata M; Castaño JP; Rodriguez-Perálvarez M; Luque RM; Gahete MD
Cancer Lett; 2021 Jan; 496():72-83. PubMed ID: 33038489
[TBL] [Abstract][Full Text] [Related]
3. SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances.
Fuentes-Fayos AC; Pérez-Gómez JM; G-García ME; Jiménez-Vacas JM; Blanco-Acevedo C; Sánchez-Sánchez R; Solivera J; Breunig JJ; Gahete MD; Castaño JP; Luque RM
J Exp Clin Cancer Res; 2022 Jan; 41(1):39. PubMed ID: 35086552
[TBL] [Abstract][Full Text] [Related]
4. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.
Jiménez-Vacas JM; Herrero-Aguayo V; Gómez-Gómez E; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Fuentes-Fayos AC; Martínez-López A; Sánchez-Sánchez R; González-Serrano T; López-Ruiz DJ; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
Transl Res; 2019 Oct; 212():89-103. PubMed ID: 31344348
[TBL] [Abstract][Full Text] [Related]
5. Mutant SF3B1 promotes malignancy in PDAC.
Simmler P; Ioannidi EI; Mengis T; Marquart KF; Asawa S; Van-Lehmann K; Kahles A; Thomas T; Schwerdel C; Aceto N; Rätsch G; Stoffel M; Schwank G
Elife; 2023 Oct; 12():. PubMed ID: 37823551
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Splicing Factor 3b Subunit 1 (SF3B1) Reduced Cell Proliferation, Induced Apoptosis and Resulted in Cell Cycle Arrest by Regulating Homeobox A10 (HOXA10) Splicing in AGS and MKN28 Human Gastric Cancer Cells.
Zhang Y; Yuan Z; Jiang Y; Shen R; Gu M; Xu W; Gu X
Med Sci Monit; 2020 Jan; 26():e919460. PubMed ID: 31927557
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity.
Zheng Q; Tang J; Aicher A; Bou Kheir T; Sabanovic B; Ananthanarayanan P; Reina C; Chen M; Gu JM; He B; Alcala S; Behrens D; Lawlo RT; Scarpa A; Hidalgo M; Sainz B; Sancho P; Heeschen C
J Exp Clin Cancer Res; 2023 Nov; 42(1):323. PubMed ID: 38012687
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells.
Zhang Q; Di C; Yan J; Wang F; Qu T; Wang Y; Chen Y; Zhang X; Liu Y; Yang H; Zhang H
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1273-1280. PubMed ID: 30963795
[TBL] [Abstract][Full Text] [Related]
9. SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis.
Yang JY; Huo YM; Yang MW; Shen Y; Liu DJ; Fu XL; Tao LY; He RZ; Zhang JF; Hua R; Jiang SH; Sun YW; Liu W
Mol Oncol; 2021 Nov; 15(11):3076-3090. PubMed ID: 33932092
[TBL] [Abstract][Full Text] [Related]
10. The long non-coding RNA DKFZp434J0226 regulates the alternative splicing process through phosphorylation of SF3B6 in PDAC.
Li J; Tong H; Li D; Jiang Q; Zhang Y; Tang W; Jin D; Chen S; Qin X; Zhang S; Xue R
Mol Med; 2021 Aug; 27(1):95. PubMed ID: 34470609
[TBL] [Abstract][Full Text] [Related]
11. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
[TBL] [Abstract][Full Text] [Related]
12. Splicing factor SF3B1 promotes endometrial cancer progression via regulating KSR2 RNA maturation.
Popli P; Richters MM; Chadchan SB; Kim TH; Tycksen E; Griffith O; Thaker PH; Griffith M; Kommagani R
Cell Death Dis; 2020 Oct; 11(10):842. PubMed ID: 33040078
[TBL] [Abstract][Full Text] [Related]
13. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
14. GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma.
Jo JH; Kim SA; Lee JH; Park YR; Kim C; Park SB; Jung DE; Lee HS; Chung MJ; Song SY
BMC Cancer; 2021 Nov; 21(1):1241. PubMed ID: 34794402
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of SF3B1 inhibits cell proliferation, invasion and migration triggering apoptosis in breast cancer via aberrant splicing.
Zhang L; Zhang X; Zhang H; Liu F; Bi Y; Zhang Y; Cheng C; Liu J
Breast Cancer; 2020 May; 27(3):464-476. PubMed ID: 31919642
[TBL] [Abstract][Full Text] [Related]
16. Titration of SF3B1 Activity Reveals Distinct Effects on the Transcriptome and Cell Physiology.
Kim Guisbert KS; Mossiah I; Guisbert E
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348896
[TBL] [Abstract][Full Text] [Related]
17. Fetal bovine serum enlarges the size of human pancreatic cancer spheres accompanied by an increase in the expression of cancer stem cell markers.
Sasaki N; Toyoda M; Hasegawa F; Fujiwara M; Gomi F; Ishiwata T
Biochem Biophys Res Commun; 2019 Jun; 514(1):112-117. PubMed ID: 31027735
[TBL] [Abstract][Full Text] [Related]
18. SF3B1 is a stress-sensitive splicing factor that regulates both HSF1 concentration and activity.
Kim Guisbert KS; Guisbert E
PLoS One; 2017; 12(4):e0176382. PubMed ID: 28445500
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma.
Vaz AP; Deb S; Rachagani S; Dey P; Muniyan S; Lakshmanan I; Karmakar S; Smith L; Johansson S; Lele S; Ouellette M; Ponnusamy MP; Batra SK
Oncotarget; 2016 Jan; 7(3):3317-31. PubMed ID: 26689992
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
